Effectiveness and safety of Fruquintinib combined SOX for conversion therapy of unresectable advanced gastric cancer (stage IV A): a single-arm, single-center, prospective clinical trial
Latest Information Update: 01 Dec 2020
At a glance
- Drugs Fruquintinib (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2020 New trial record